Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia – a review of its characteristics

References

• Ismail-BeigiFGlycemic management of type 2 diabetes mellitusN Engl J Med20123661319132722475595
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20093219320318945920
   PubMed Web of Science ®Google Scholar
• HandelsmanYMechanickJIBlondeLAmerican Association of Clinical Endocrinologists Medical Guidelines for the Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan: executive summaryEndocr Pract201117Suppl 228730221474421
   PubMed Web of Science ®Google Scholar
• Ismail-BeigiFGravenTBenerjiMAEffect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trialLancet201037641943020594588
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelM10-year follow up of intensive glucose control in type 2 diabetesN Engl J Med20083582545255918539917
   PubMed Web of Science ®Google Scholar
• PatelAMacMahonSChalmersJIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med20083582560257218539916
   PubMed Web of Science ®Google Scholar
• NauckMAMeiningerGShengDEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab2007919420517300595
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaRPEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab2007917518517300593
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2014Diabetes Care201437Suppl 1S5S1324357214
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)JAMA20012852486249711368702
   PubMed Web of Science ®Google Scholar
• IronsBKKroonLALipid management with statins in type 2 diabetes mellitusAnn Pharmacother2005391714171916118264
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trialLancet200436468569615325833
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupEffects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20536 high-risk individuals: a randomized controlled trialLancet20113782013202022115874
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trialLancet20033612005201612814710
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves combination therapy Juvisync Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm274748.htmAccessed January 5, 2015
   Google Scholar
• Juvisync [package insert]Whitehouse Station, NJ, USAMerck and Co Inc2012
   Google Scholar
• NathanDFinding new treatments for diabetes – how many, how fast … how good?N Engl J Med200735643744017267901
   PubMed Web of Science ®Google Scholar
• MillerSASt OngeELSitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesAnn Pharmacother2006401336134316868220
   PubMed Web of Science ®Google Scholar
• Merck and Co IncJuvisync: prescribing information Available from: http://www.januvia.com/sitagliptin/januvia/hcp/juvisync/index.jspAccessed January 5, 2015
   Google Scholar
• BergmanAJStevensCZhouYPharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteersClin Ther200628557216490580
   PubMed Web of Science ®Google Scholar
• BergmanAJCoteJMaesAEffect of sitagliptin on the pharmacokinetics of simvastatinJ Clin Pharmacol20094948348819204138
   PubMed Web of Science ®Google Scholar
• HermansenKKipnesMFanurikDEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab2007973374517593236
   PubMed Web of Science ®Google Scholar
• HarashimaSIOguraMTanakaDSitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycemic control and insulin secretion capacity in type 2 diabetesInt J Clin Pract20126646547622512606
   PubMed Web of Science ®Google Scholar
• Merck Provides Update on Combination Medicine JUVISYNC™ (sitagliptin and simvastatin) Tablets Available from: http://www.mercknewsroom.com/news/company-statements/merck-provides-update-combination-medicine-juvisync-sitagliptin-and-simvastatinAccessed January 5, 2014
   Google Scholar
• AschnerPChanJOwensDRInsulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicenter, randomized open-label trialLancet20123792262226922683131
   PubMed Web of Science ®Google Scholar
• LindholmLHMajor benefits from cholesterol lowering in patients with diabetesLancet20123612000200112814705
   PubMedGoogle Scholar
• WannerCKraneVMarzWAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisN Engl J Med200535323824816034009
   PubMed Web of Science ®Google Scholar
• KeechAColquhounDBestJSecondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucoseDiabetes Care2003262713272114514569
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysisBMJ20033261423142712829554
   PubMed Web of Science ®Google Scholar
• ZhouZRahmeEPiloteLAre statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease preventionAm Heart J200615127328116442888
   PubMed Web of Science ®Google Scholar
• MillsEJWuPChongGEfficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170255 patients from 76 randomized trialsQ J Med2001104109124
   Google Scholar
• RidkerPMPradhanAMacFadyenJGCardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trialLancet201238056557122883507
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationInformation for healthcare professionals – acute pancreatitis and sitagliptin (marketed as Januvia or Janumet) Available from: http://www.fda.gov/Drug/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm183764.htmAccessed January 5, 2015
   Google Scholar
• EngelSSWilliams-HermanDEGolmGTSitagliptin: review of preclinical and clinical data regarding incidence of pancreatitisInt J Clin Pract20106498499020412332
   PubMed Web of Science ®Google Scholar
• GarcRChenWPendergrassMAcute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysisDiabetes Care2010332349235420682680
   PubMed Web of Science ®Google Scholar
• EganAColmanEWeighing the benefits of high-dose simvastatin against the risk of myopathyN Engl J Med201136528528721675881
   PubMed Web of Science ®Google Scholar
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupIntensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomised trialLancet20103761658166921067805
   PubMed Web of Science ®Google Scholar
• KaoDPKohrtHEKuglerJCase report: renal failure and rhabdomyolysis associated with sitagliptin and simvastatin useDiabet Med2008251229123019046202
   PubMed Web of Science ®Google Scholar
• MaTTienLFangCLStatins and new-onset diabetes: a retrospective longitudinal cohort studyClin Ther2012341977198322939164
   PubMed Web of Science ®Google Scholar
• [No authors listed]Sitagliptan and simvastatin (Juvisync)Med Lett Drugs Ther20115389
   Web of Science ®Google Scholar